Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.

Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, Tritt K, Krawczyk J, Kettler C, Egger C, Rother WK, Loew TH.

J Clin Psychopharmacol. 2005 Jun;25(3):211-7.

PMID:
15876898
2.

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.

Egger C, Muehlbacher M, Schatz M, Nickel M.

J Clin Psychopharmacol. 2007 Oct;27(5):475-8.

PMID:
17873679
3.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Narula PK, Rehan HS, Unni KE, Gupta N.

Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001. Epub 2010 Mar 7.

PMID:
20207521
4.

Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study.

Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK, Nickel C, Krawczyk J, Mitterlehner FO, Rother WK, Loew TH, Kaplan P.

Clin J Pain. 2006 Jul-Aug;22(6):526-31.

PMID:
16788338
5.

Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH.

J Clin Psychiatry. 2004 Nov;65(11):1515-9.

PMID:
15554765
6.

Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study.

Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, Fartacek R, Lahmann C, Buschmann W, Tritt K, Bachler E, Mitterlehner F, Pedrosa Gil F, Leiberich P, Rother WK, Egger C.

J Clin Psychopharmacol. 2006 Feb;26(1):61-6.

PMID:
16415708
7.

Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.

Vieta E, Sánchez-Moreno J, Goikolea JM, Colom F, Martínez-Arán A, Benabarre A, Corbella B, Torrent C, Comes M, Reinares M, Brugue E.

J Clin Psychopharmacol. 2004 Aug;24(4):374-8.

PMID:
15232327
8.

Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study.

Nickel C, Lahmann C, Tritt K, Muehlbacher M, Kaplan P, Kettler C, Krawczyk J, Loew TH, Rother WK, Nickel MK.

J Affect Disord. 2005 Aug;87(2-3):243-52.

PMID:
15985295
9.

The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.

Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, Després JP.

Eur J Clin Pharmacol. 2007 Feb;63(2):123-34. Epub 2007 Jan 3.

PMID:
17200837
10.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.

Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7.

11.

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.

Int J Obes (Lond). 2007 Jan;31(1):138-46. Epub 2006 May 16.

PMID:
16703004
12.

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group.

Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410.

PMID:
15486569
13.

Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial.

Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, Lahmann C, Leiberich PK, Krawczyk J, Kettler C, Rother WK, Loew TH, Nickel MK.

Int J Eat Disord. 2005 Dec;38(4):295-300.

PMID:
16231337
14.
15.

Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.

Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):539-45. doi: 10.1089/cap.2009.0042.

PMID:
19877978
16.

Topiramate in migraine prevention: a double-blind, placebo-controlled study.

Storey JR, Calder CS, Hart DE, Potter DL.

Headache. 2001 Nov-Dec;41(10):968-75.

PMID:
11903524
17.

Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, Krawczyk J, Leiberich PK, Rother WK, Loew TH.

Biol Psychiatry. 2005 Mar 1;57(5):495-9.

PMID:
15737664
18.

Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder.

Claudino AM, de Oliveira IR, Appolinario JC, Cordás TA, Duchesne M, Sichieri R, Bacaltchuk J.

J Clin Psychiatry. 2007 Sep;68(9):1324-32.

PMID:
17915969
19.

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.

Kim JH, Yim SJ, Nam JH.

Schizophr Res. 2006 Feb 15;82(1):115-7. Epub 2005 Dec 2. No abstract available.

PMID:
16326074
20.

Supplemental Content

Support Center